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Asthma and chronic obstructive pulmonary disease (COPD) have both been historically
associated with significant morbidity and financial burden. These diseases can be
induced by several exogenous factors, such as pathogen-associated molecular patterns
(PAMPs) (e.g., allergens and microbes). Endogenous factors, including reactive oxygen
species, and damage-associated molecular patterns (DAMPs) recognized by toll-like
receptors (TLRs), can also result in airway inflammation. Asthma is characterized by
the dominant presence of eosinophils, mast cells, and clusters of differentiation (CD)4+
T cells in the airways, while COPD typically results in the excessive formation of
neutrophils, macrophages, and CD8+ T cells in the airways. In both asthma and COPD,
in the respiratory tract, TLRs are the primary proteins of interest associated with the
innate and adaptive immune responses; hence, multiple treatment options targeting
TLRs are being explored in an effort to reduce the severity of the symptoms of these
disorders. TLR-mediated pathways for both COPD and asthma have their similarities and
differences with regards to cell types and the pro-inflammatory cytotoxins present in the
airway. Because of the complex TLR cascade, a variety of treatments have been used to
minimize airway hypersensitivity and promote bronchodilation. Although unsuccessful at
completely alleviating COPD and severe asthmatic symptoms, new studies are focused
on possible targets within the TLR cascade to ameliorate airway inflammation.
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INTRODUCTION
Asthma and chronic obstructive pulmonary disease (COPD) are two respiratory diseases
characterized by an accumulation of inflammatory cells in the respiratory tract, which leads
to subsequent airflow obstruction (Singh and Busse, 2006; Quint and Wedzicha, 2007). It is
estimated that 25 million people in the United States alone are affected by asthma (Centers
of Disease Control and Prevention, 2013), and approximately 20 million people are diagnosed
with COPD (American Lung Association). Ranking as the third leading cause of death in the
United States, COPD shares similar symptomatic features with asthma. However, the mechanisms
underlying the pathophysiology of these two diseases are distinct (Barnes, 2008). For instance, the
instigators of airway inflammation are different for COPD (neutrophils) and asthma (eosinophils)
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(Barnes, 2000). Most notably, patients with COPD experience
progressive and irreversible structural alterations, including
airway remodeling and alveolar destruction, which ultimately
result in breathing difficulties; whereas airway obstruction
is often reversible in asthma (Barnes, 2008; Baines et al.,
2011). Periodic exacerbations of COPD can worsen respiratory
symptoms and markedly increase the risk of mortality (Domej
et al., 2014).
Airway inflammation plays an essential role in the
development of both asthma and COPD. Undoubtedly,
variations in the inflammatory process between the two diseases
underlie the unique immunopathologies of asthma and COPD.
Emerging evidence suggests that toll-like receptors (TLRs)
may be associated with the aberrant stimulation of immune
responses, possibly contributing to the chronic inflammation
seen in asthma (Phipps et al., 2007). TLRs are a subgroup
of pattern recognition receptors (PRRs), which are antigen-
sensitive, responsible for innate immunity (Kawai and Akira,
2010). Within the TLR family, there are 10 members that are
active in humans (Warren, 2005). Generally, most of these TLRs
have been split into two sub-groups. TLR1, TLR2, TLR4, TLR5,
TLR6, and TLR11 comprise the first group and are primarily
expressed on the cell surface; the function of this group is to
recognize the components of microbial membranes (Blasius and
Beutler, 2010; Kawai and Akira, 2010). The second sub-group
is composed of TLR3, TLR7, TLR8, and TLR9. These TLRs are
expressed intracellularly in vesicles (e.g., lysosomes, endosomes,
and the endoplasmic reticulum) and can target microbial nucleic
acids (Blasius and Beutler, 2010; Kawai and Akira, 2010). Serving
as the first line of host defense, the airway epithelium utilizes
a variety of receptors, including TLRs, to detect antigens and
infectious microorganisms. The lung and respiratory tract are
particularly susceptible to pathogens and allergens because of the
constant exposure of inhaled air. Additionally, TLRs recognize
exogenous pathogen-associated molecular patterns (PAMPs) and
host-derived damage-associated molecular patterns (DAMPs;
Lafferty et al., 2010). The activation of TLRs through these
means selectively induce inflammation, inflammatory cell
recruitment, and cytokine release. In particular, TLR2 and TLR4
are regarded as the major TLRs responsible for sustaining the
inflammatory responses in both asthma and COPD. However,
altering the immunoreactivity and expression of TLRs may
result in an impaired immune response, which is marked by
abnormal inflammation in the aforementioned diseases (Lafferty
et al., 2010). This review will highlight the roles of TLRs in
inflammation and their association to the physiopathology of
asthma and COPD, as well as discuss the potential for TLR-based
treatment of these diseases.
MOLECULAR CHARACTERISTICS OF
ASTHMA AND COPD
Persistent inflammation and airflow obstruction are the major
characteristics of asthma and COPD. However, the patterns
of inflammation and the immunological mechanisms that
lead to the airway structural alterations are different for the
respective diseases (Barnes, 2000, 2008). Inflammation in the
larger conducting airways is mainly observed in asthma. In
contrast, COPD predominantly affects the lung parenchyma and
smaller airways (Barnes, 2008). Asthma is characterized by the
presence of eosinophils, mast cells, and CD4+ T lymphocytes;
whereas COPD is distinguished by the dominance of neutrophils,
macrophages and CD8+ T lymphocytes in the respiratory tract
(Buist, 2003; Baines et al., 2011; Athanazio, 2012). T cell
activation is dependent upon the antigen presenting cells (e.g.,
dendritic cells) and plays a substantial role in inflammation
(Shalaby and Martin, 2010).
In asthma, IgE binds to receptors found on the surface
of mast cells, thus initiating an allergic response (Gauvreau
et al., 2015). The recruited mast cells subsequently degranulate
to release histamine, an organic compound known to increase
hypersensitivity and inflammation, thereby leading to the
development of bronchoconstriction (Figure 1; Jutel et al., 2009).
Bronchoconstriction is both spontaneous and reversible in
asthmatics, and is induced by the hyperreactive smooth muscle
surrounding the bronchioles (Athanazio, 2012). Moreover,
structural changes, such as subepithelial fibrosis and smooth
muscle cell hyperplasia and hypertrophy, can contribute to
the thickening of asthmatic airways (Barnes, 2008). In most
asthma cases, there is a predominant expression of Th2-type
cytokines, including interleukin (IL)-4, IL-5, and IL-13, which
are all activated by the transcription factor GATA-binding
protein 3 (GATA3; Zhu et al., 2006). These Th2-type cytokines
result in the increased migration of eosinophils and mast
cells. One of the consequences of eosinophilic inflammation is
epithelial shedding, which is frequently observed in biopsies from
asthmatic patients (Barnes, 2000).
Interestingly, the activation of mast cells is not evident in
patients with COPD (Barnes, 2008). Instead, macrophages are
recruited to the COPD airway via the release of the cytokine
interferon γ (IFN-γ) by either CD4+ T cells or Th1 cells
(Barnes, 2004). The reduction in airway capacity originates
from cellular damage found in COPD. Several initiators can
cause this destruction, including exposure to noxious particles,
such as cigarette smoke and exogenous reactive oxygen species
(ROS; Zuo et al., 2014). In addition to IFN-γ, other major
cytokines expressed in COPD are IL-1, IL-8 (also known
as CXCL8), leukotriene B4, granulocyte-macrophage colony-
stimulating factor (GM-CSF), and tumor necrosis factor-α (TNF-
α) (Kim and Rhee, 2010; Athanazio, 2012). The expression of
IFN-γ, IL-8, GM-CSF, and TNF-α lead to the activation and
migration of neutrophils to the airways (Figure 1; Wright et al.,
2010). Moreover, COPD differs from asthma in the expression
of certain TLRs. For instance, in asthma, the presence of TLR4
is lowered in the respiratory tract, whereas TLR4 expression is
elevated in COPD patients, possibly as a result of the cellular
breakdown in the airways (Bezemer et al., 2012).
ROLE OF TLR DURING INFLAMMATION
The epithelium of the respiratory tract contains a myriad of
TLRs, which participates in the activation of immune responses.
Particularly, the role of specific TLRs during inflammation
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FIGURE 1 | Immunological mechanisms involving TLR2/TLR4 and Th1/Th2 immunity. Abbreviations: PAMPs, pathogen-associated molecular patterns; ROS,
reactive oxygen species; IL, interleukin; IFN-γ, interferon-γ; TLR, toll-like receptor; CS, cigarette smoke; CD4, cluster of differentiation 4; CD8, cluster of differentiation
8; Th1, T helper cell type 1; Th2, T helper cell type 2; Gram (−), gram-negative bacteria; Gram (+), gram-positive bacteria; IgE, Immunoglobulin E; GATA-3, GATA
binding protein 3; TNF-α, tumor necrosis factor-α; GM-CSF, Granulocyte-macrophage colony-stimulating factor; NAC, N-Acetyl-L-cysteine; H2, molecular hydrogen;
H2S, dihydrogen sulfide.
has suggested their involvement in the pathogenesis of asthma
and COPD (Lafferty et al., 2010). TLRs are also expressed
in resident lung cells, such as alveolar macrophages, and
other infiltrating cells (Lafferty et al., 2010). TLR4-expressing
fibroblasts and epithelial cells have been found to contribute
to the localized inflammatory response (Buckley, 2011). These
cells have an anchor-like function, utilizing their ability to
attract and immobilize leukocytes through the release of several
chemokines and cellular adhesion molecules (Buckley et al.,
2001). When the leukocytes persist in the respiratory tract,
chronic inflammation is an expected outcome (Buckley et al.,
2001; Buckley, 2011).
Inflammatory Aspects of Asthma
TLR2 and TLR4 are the most relevant to the onset of
asthma and to the inflammatory responses underlying asthmatic
exacerbations. TLR4 detects Gram-negative bacteria through
their lipopolysaccharides (LPS; Lafferty et al., 2010), while
TLR2 plays a large role in recognizing Gram-positive bacteria
(Jiang et al., 2006). As described earlier, Th2 cells, mast cells,
and eosinophils are commonly associated with the innate and
adaptive immune responses in asthma (Figure 1; Walsh et al.,
2010). The recognition of allergens, such as house dust mites
(HDM), can activate TLR4 and subsequently allergen-specific
Th2 cells (Lafferty et al., 2010). TLR2 promotes Th2-biased
immune responses, which may be correlated to the Th1/Th2
imbalance in asthma (Phipps et al., 2007). There are two distinct
pathways in TLR signaling: myeloid differentiation factor 88
(MyD88)-dependent and MyD88-independent. Both pathways
are crucial in regard to the innate immune response. MyD88
and Toll/IL-1 receptor-domain containing adapter-inducing
interferon-β (TRIF) bind independently to TLRs, leading to
the release of cytokines such as TNF-α, IL-1β, CXCL10, IL-6,
and IFN-γ (Piras and Selvarajoo, 2014). During acute asthmatic
exacerbations, the cleavage products of proteinases, such as
fibrinogen, bind to TLR4s that are present in both the airway
epithelium and macrophages, and the binding of these products
results in allergic inflammation (Millien et al., 2013). In addition,
asthmatic patients who ultimately die have increased expressions
of TLR2, TLR3, and TLR4, suggesting their potential role in the
development of severe or even fatal asthmatic exacerbations (Kim
and Rhee, 2010; Ferreira et al., 2012).
Genetic Factors in Asthma
Genetic polymorphisms play a significant role in how individuals
respond to diseases. The genetic make-up of a person can make
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them more or less susceptible to a specific disease (Lee et al.,
2012). Similarly, genetic polymorphisms affect the susceptibility,
severity, and responsiveness of asthmatic patients to specific
allergens. Variants of the TLR4 gene may either increase or
decrease the sensitivity of the receptor to allergens (Cho et al.,
2011). Zhang et al. indicated that polymorphisms in TLR4
have an impact on the responsiveness of the receptor to
pathogens (Zhang et al., 2011). During this study, several types
of polymorphisms were examined in an attempt to discover the
particular combination of genes responsible for the susceptibility
and severity of asthma. The TT homozygote allele of the TLR
gene rs1927914 has deleterious effects for the forced expiratory
volume in 1 s (FEV1) (Zhang et al., 2011). A decreased FEV1
suggests a reduced lung capacity and increased airway resistance.
Furthermore, the C allele of rs1927914 and the A allele of
both rs10983755 and rs1927907 lessen the severity of asthma
(Zhang et al., 2011). In addition to TLR4, polymorphisms
present in the TLR2 gene are also associated with the risk
of asthma development and overall lung function (Gao et al.,
2013). The genotype of the TT variant of the homozygous
polymorphism rs7656411 in TLR2 may reduce the incidence
of asthma (Qian et al., 2010). It has been shown that the T
allele of the rs2381289 single nucleotide polymorphism (SNP)
in TLR6 contributes to the development of allergic rhinitis
and asthma, while the A allele of rs11466651 SNP in TLR10
is negatively associated with asthma development (Qian et al.,
2010).
Inflammatory Aspects of COPD
Several TLRs, including TLR2, TLR4, and TLR9, participate in
the pathogenesis of COPD. Themajor risk factors associated with
COPDdevelopment include cigarette smoking and the inhalation
of air pollutants (Bezemer et al., 2012). There is a high correlation
between cigarette smoke exposure and the increased gene
expression of TLR4 and TLR9 as well as cytokine overproduction
(Nadigel et al., 2011; Bezemer et al., 2012; Freeman et al., 2013).
Both TLR4 and TLR9 have been shown to contribute to the
release of IL-8 from CD8+ T cells (Nadigel et al., 2011). Through
the upregulation of IL-8, TLR9 elicits an inflammatory response
by initiating neutrophil recruitment (József et al., 2006; Mortaz
et al., 2010). It is also known that TLR4 deficiency promotes
emphysema (An et al., 2012). When exposed to cigarette smoke,
alveolar apoptosis increased in TLR4-deficient mice, suggesting
a protective role of TLR4 in cell regulation and apoptosis
prevention (An et al., 2012). Interestingly, mice that lack TLR4
expression are more susceptible to oxidative stress due to an
upregulation of NADPH oxidase (Nox) 3 (Zhang et al., 2006;
Kampfrath et al., 2011). It was proposed by Zhang et al. that TLR4
acts as a suppressor of Nox3, therefore regulating the release of
ROS (Zhang et al., 2006). Thus, it is possible that in the absence
of TLR4, ROS reaches harmful levels and ultimately leads to
cellular apoptosis and emphysema. Experimentally, emphysema
progression in TLR4-deficient mice can be halted by a Nox
inhibitor or Nox3 siRNA (Zhang et al., 2006). Furthermore, a
dramatic decrease in antioxidant activity, particularly glutathione
levels, was observed in TLR4 knockout mice (Zhang et al.,
2006).
Additionally, TLRs are considerably involved with
exacerbations of COPD. Research has indicated that MyD88
works in conjunction with TLR4 to upregulate IL kinases and
increase IL production (Doz et al., 2008). The interactions
between MyD88, TLR4 and IL-1 receptor type I (IL1R1) can
lead to acute lung inflammation in COPD patients. Moreover,
neutrophil recruitment due to cigarette smoke exposure is
dependent on TLR4/MyD88/IL1R1 signaling (Doz et al., 2008;
Sarir et al., 2008). TLR2 and TLR4 are the primary mediators
that elicit immune responses to microbial invasion in the
respiratory tract (Figure 1; Oliveira-Nascimento et al., 2012).
Patients with COPD have increased TLR1 and TLR2 expression
on CD8+ T cells and which may contribute to lung damage and
alveolar destruction (Freeman et al., 2013). However, it was also
discovered that LPS-induced TLR4 expression is reduced in the
lymphocytes of smokers with and without COPD (Knobloch
et al., 2011). Therefore, a thorough examination of immune cells
and the expression of specific TLRs are needed in future research.
Genetic Factors in COPD
Several polymorphisms are known to influence the likelihood
of developing COPD. In particular, SNPs have been shown to
impair TLR signaling by reducing the responsiveness of TLRs
and the resistance to bacteria and viruses (Cheng et al., 2007;
Bronkhorst et al., 2013). Previous research has indicated that
the presence of the TLR4-T399I polymorphism increases the
risk for COPD development by a factor of 2.4 (Speletas et al.,
2009). Several SNPs present in TLR2 are highly associated with
lung function. Accordingly, Budulac et al. suggested that both
TLR2 SNPs (rs1898830 and rs11938228) are involved in FEV1
decline, whereas the SNPs rs7656411 and rs4696480 are related to
increased FEV1 (Budulac et al., 2012). The TLR2 SNP rs11938228
may be responsible for an acute increase in neutrophils and
macrophages. Likewise, the SNPs rs12377632 and rs10759931 in
TLR4 are highly associated with inflammation in the lung and
respiratory tracts (Budulac et al., 2012). These studies confirm
the association between specific polymorphisms and COPD,
warranting additional investigations of this area.
ROLE OF ROS IN TLR REGULATION IN
ASTHMA AND COPD
The accumulation of ROS is also evident in patients with COPD
and asthma (Zuo et al., 2012, 2013). ROS are beneficial during
immune responses, as their presence aids in the destruction
of microbes. However, excessive ROS can directly initiate
inflammatory responses and negatively affect tissue functions
and cellular structures, including DNA and lipids (Figure 1;
Kirkham and Rahman, 2006; Zuo et al., 2011a,b, 2015). These
oxidants are produced endogenously by mitochondria, NADPH
oxidase, phagocytes, and lymphocytes, or exogenously from
sources such as cigarette smoke and ozone (Zuo et al., 2011c;
Hernandez et al., 2012). The overproduction of ROS may lead
to inflammation via the activation of transcription factors such
as nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-κB; Rahman, 2006). In addition, ROS can alter the
conformation of proteins, which then may bind to antibodies
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and generate a false immune response, promoting smoothmuscle
cell hyperactivity via calcium influx (Tetley, 2005; Kirkham et al.,
2011). ROS also stimulate TLR2 and TLR4 through MyD88-
dependent pathways, inducing cellular damage and elevated
levels of DAMPs (Hansel and Barnes, 2009). Furthermore,
oxidative stress contributes to the sensitization of allergens by
generating an enhanced allergic immune response (Shalaby et al.,
2013), thus exacerbating the development of allergic asthma. The
presence of ROS in the innate immune response is intended
to destroy invading pathogens, yet it may generate undesired
cellular damage (Figure 1; Quinn and Schepetkin, 2009; Delfino
et al., 2011).
TLR-BASED THERAPY FOR ASTHMA AND
COPD
As reported by the Mayo Clinic, the typical treatment for asthma
exacerbations includes the inhalation of corticosteroids (Townley
and Suliaman, 1987). In the treatment of COPD, a combination
of long acting bronchodilators and inhaled corticosteroids is
typically used (Wedzicha et al., 2012). Corticosteroids are known
to enhance β-adrenergic responses and repress inflammatory
responses in the airway (Tamm et al., 2012). However, in severe
cases of asthma and COPD, corticosteroids are ineffective in
alleviating symptoms (Kirkham and Rahman, 2006; Brusselle
et al., 2011; Barnes, 2013). This is likely due to overwhelming
oxidative stress and subsequent DNA damage, leading to
decreased activity of transcriptional co-repressors such as
histone deacetylase-2 (HDAC-2) (Kirkham and Rahman, 2006).
Therefore, antioxidant treatments may reduce the production
of DAMPs by scavenging ROS and consequently inhibiting the
activation of more TLRs (Kirkham and Rahman, 2006).
Drugs that target TLRs can be classified as either agonists
or antagonists. TLR agonists increase the response of receptors,
while antagonists generally mitigate the responses by attenuating
inflammation (Xiang et al., 2010). In allergic asthma, chronic
inflammation is caused by exposure to allergens. In asthma
treatment, antagonists targeting muscarinic receptors are used
to relax the smooth muscle of the airway to promote
bronchodilation (Barnes, 2006; Moulton and Fryer, 2011).
Shalaby et al. observed that an intranasal administration of
Protollin, a compound composed of both TLR2 and TLR4
ligands, is effective in inhibiting allergic responses (Shalaby et al.,
2012). Another study conducted by Xirakia et al. showed that the
administration of a compound commonly known as Resiquimod
or R-848, a TLR7 agonist, was beneficial in the suppression of
allergic airway diseases (Xirakia et al., 2010). TLR7 has anti-
inflammatory characteristics, and its activation is known to curb
inflammation through the reduction of leukocytes entering the
airways. Most notably, R-848 diminishes leukocyte recruitment,
as well as the production of IL-5 and IL-13 (Drake et al.,
2012). The protective mechanisms of TLRs are thought to arise
from the reorientation of the immune system to reduce Th2
function, including the production of Th2 cytokines, eosinophils,
and bronchial hypersensitivity, resulting in decreased airway
inflammation (Aumeunier et al., 2010; Xirakia et al., 2010).
KEY STUDIES IN TLRS—AN UPDATE
FROM 2010 TO 2014
TLRs have become a protein of interest and are accepted as
a major site for transmitting inflammatory responses in the
mucosal lining of the lungs and nasal pathways (Lafferty et al.,
2010). However, the activation of the innate immunity in the
nasal and lung mucosa is TLR- and PAMP-specific. Ryu et al.
observed that HDM-derived β-glucans trigger innate immune
responses in the nasal mucosa of mice via TLR2, whereas LPS
induces TLR4 signaling in the mucosa of the lower respiratory
region (Ryu et al., 2013). The study also found that dual
oxidase 2-generated ROS regulates the activation of the β-glucan-
induced TLR2 pathway and the LPS-TLR4 interaction (Ryu et al.,
2013). The interaction consists of the Toll/IL1R homology (TIR)
domain made of the accessory protein CD14, which binds to
LPS, TLR4, and MD2 protein. Once LPS is bound, the TIR
domain communicates with MyD88 to further relay several
kinase activations, such as IL-1 receptor kinase (IRAK), until a
response is triggered (Park and Lee, 2013). Collectively, these
findings suggest a promising role for TLRs in the treatment of
both allergic rhinitis and asthma.
Lucas et al. suggested that TLRs play a pathogenic role in the
development of many human diseases, including cardiovascular
disease, Parkinson’s disease, and autism (Lucas andMaes, 2013b).
Additionally, the study examined several methods that attempt
to neutralize the effects of TLRs in disease development (Lucas
and Maes, 2013b). Several different PAMPs and DAMPs can
be recognized by specific TLRs. For instance, the interaction
that occurs between LPS and TLR4 involves the binding of
LPS to CD14, an accessory protein of TLR4. LPS is then
transferred to myeloid differential protein-2, another TLR4
accessory molecule, initiating the downstream signaling pathway
of TLR4 (Lucas and Maes, 2013b). Other factors known
to affect the TLR pathways were also discussed, including
ozone, particular matter, bacteria and viruses, aerosol particles,
certain metals, adjuvants, vaccines, pesticides, preservatives,
ionizing radiation, inhaled toluene, TLR adaptations, ROS, and
Oxidized 1-palmitoyl-2-arachidonyl-sn-3 (OxPAPC; Lucas and
Maes, 2013b). Synthetic anti-LPS peptides (SALPs) have been
developed as treatments that target LPS. SALPs bind to LPS
and prevent TLR4 activation, thereby attenuating the host
inflammatory response (Lucas and Maes, 2013b). These SALPs
are useful because they effectively neutralize endotoxins at low
concentrations, preventing endotoxic shock. There are several
antagonists known to suppress the MyD88-dependent and -
independent pathways by inhibiting the TANK-binding kinase
1 (TBK1), including compounds found in common traditional
Chinesemedicines, such as green tea and ginger (Lucas andMaes,
2013b). Targeting the MyD88 pathway may provide potential
treatment options because all TLRs, except TLR3, depend on this
pathway. Antioxidant treatments, such as N-acetyl-L-cysteine
(NAC) and flavonoids, scavenge excess ROS, further reducing the
formation of DAMPs (Lucas and Maes, 2013b). By modulating
the responsiveness of TLRs through antioxidants, multiple TLR-
dependent human diseases may be significantly improved (Lucas
and Maes, 2013b). TLR4 antagonists can target the TLR radical
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TABLE 1 | Traditional medicine with pharmacologically active substances and their effects.
Plants/Pharmacologically active
substances
Effects Citations
Green Tea (Camellia sinensis)
Epigallocatechin gallate
• Potent antioxidant
• Decreases TLR4 activity
• Excessive exposure leads to green tea-induced asthma
Shirai et al., 2003; Wu et al., 2012; Bao et al., 2014
Turmeric (Curcuma longa) Curcumin • Prevents accumulation of inflammatory cells in airways
• Treatments attenuated in an asthma model the Treg/Th17 balance
• Reduces NF-κB translocation in cell culture and mice asthma
model
Oh et al., 2011; Ma et al., 2013; Chauhan et al., 2014
True cinnamon (Cinnamomum verum)
Cinnamaldehyde, cinnamic acid, and
cinnamate
• Lowers expression of TLR4, MyD88 and NF-κB
• Expresses antimicrobial, antiviral and antioxidant activities
Shen et al., 2012; Lucas and Maes, 2013a
Ginger (Zingiber officinale)/6-gingerol,
8-gingerol, 6-shogaol
• Anti-inflammatory by modulation of STAT3 and MAPKs signaling
pathways
• 6-Shogaol induces AhR regulation through transcription factors
and gene expression
• Reduces airway hyperresponsiveness, by altering Ca2+ regulation,
relaxes airway smooth muscle
Townsend et al., 2013; Prasad and Aggarwal, 2014;
Yoshida et al., 2014
Xing-ren (Semen Armeniacae
Amarum)/Amygdalin
• Inhibits expression of TNF-α and IL-1β Huang et al., 2013
Xinjiang liquorice, (Glycyrrhiza inflata),
Flavonoids†
• Attenuation of allergic airway inflammation
• Inhibition of cytokines, e.g., IL-4, IL-5 and IL-13
Chu et al., 2013; Fu et al., 2013
†Licochalcone A, 5-(1,1-Dimethylallyl)-3,4,4′-trihydroxy-2-methoxychalcone, Licochalcone B, Echinatin, Glycycoumarin, Glyurallin B.
AhR, aryl hydrocarbon receptor; Ca2+, calcium ion; IL, interleukin; MAPK, mitogen-activated protein kinase; MyD88, myeloid differentiation primary response gene (88); STAT3, signal
transducer and activator of transcription 3; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; Th17, T helper 17 cell; TLR, toll like receptor; TNF-α, tumor necrosis
factor alpha; Treg, regulatory T cell.
cycle. Interestingly, several plants used in traditional Chinese
medicine were used to optimize the TLR radical cycle effects
(Table 1).
TLR activation, pro-inflammatory cytokine production, ROS
release, and the production of DAMPs that reactivate TLRs
all comprise the TLR radical cycle (Figure 2). Particularly,
TLR4 activation results in the translocation of transcription
factors, such as NF-κB and activator protein 1 (AP1), from
the cytoplasm into the nucleus, which in turn initiates the
transcription of pro-inflammatory cytokines, such as TNF-
α, IL-1, IL-6, and IL-8 (Lucas and Maes, 2013b). These
pro-inflammatory cytokines and similar compounds, such as
extracellular RNA, can attract different leukocytes to release
ROS (Fischer et al., 2012). Typical types of ROS, such as
hypochlorite (OCl−), hydrogen peroxide (H2O2), singlet oxygen
(O2(a
1
1g)), hydroxyl radical (
•OH) and superoxide (O2
•−),
can destroy bacteria and viruses and degrade lipids, proteins,
and sugars (Uy et al., 2011; Bachi et al., 2013; Nyström et al.,
2013). Some of the oxidized compounds that result from
exposure to ROS include oxidized phospholipids and degraded
hyaluronan fragments (Kadl et al., 2011; Muto et al., 2014).
These altered molecules act as DAMPs, and each has the ability
to activate TLRs, most notably TLR4 (Figure 2; Lucas and
Maes, 2013b). This activation of TLR4 by DAMPs is the final
stage of the cycle. DAMPs then “reinitiate” a new round of
the cycle consisting of PRRs, pro-inflammatory cytokines, ROS,
and DAMPs (Lucas and Maes, 2013b). This cycle becomes
independent of its initial trigger and establishes a dramatic
amplification of the immune response (Lucas and Maes, 2013b).
The ongoing cycle is controlled by multiple factors, and there
is no clear initiation or termination. The cycle provides a
multitude of targets ranging from TLRs to oxidative radicals for
suppressing the immune response. Further research is needed to
determine which of these could translate into effective treatment
approaches.
TLR5 and TLR7 are epithelial receptors that have both been
shown to participate in respiratory inflammation (Shikhagaie
et al., 2014). Specifically, TLR5 aids in the detection of bacterial
flagellin protein, a component of flagellated bacteria, and
enhances flagellin-specific CD4+ T cell responses and adaptive
immunity (Letran et al., 2011). In addition, TLR7 represses host
inflammatory responses by promoting bronchodilation, as well as
decreasing airway hyperreactivity and inflammation (Drake et al.,
2012). The expressions of TLR5 and TLR7 are decreased in the
epithelium of patients with severe asthma compared with healthy
individuals and those with moderate asthma. This decreased
expression may affect the innate immune response (Shikhagaie
et al., 2014).Metcalfe et al. studied the effects of several PAMPs on
TLR expression in alveolar macrophages in patients with COPD,
such as cigarette smoke extract (CSE), common LPS, Pam3CSK4,
and phase 1 flagellin (FliC) (Metcalfe et al., 2014). The study
found that CSE suppressed the TLR-induced production of TNF-
α, IL-6, and IL-10. However, IL-8 production was unaffected. An
analysis of gene expression illustrated that CSE inhibited LPS-
activated TNF-α transcription but did not affect the transcription
of IL-8 in alveolar macrophages. This attenuating effect has been
correlated to a decreased activation of p38, p65, and extracellular
signal regulated kinase (ERK) (Metcalfe et al., 2014).
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FIGURE 2 | The TLR radical cycle. The TLR4 receptor on any TLR4
expressing cell, e.g., an epithelial cell or a fibroblast is triggered by PAMPs
and/or DAMPs. These immobile cells are part of the inflammatory cycle and
they regulate the location of the inflammation. After TLR4 is activated,
pro-inflammatory cytokines are released and started to attract macrophages,
mast cells and neutrophils, ultimately leading to ROS production. ROS attack
microbes, but also cause collateral damage to the cell. Endogenous
molecules are modified by ROS and act as DAMPs to reactivate TLR4. The
loop is then complete and another cycle may begin. The result of the cycle is
the persistence of chronic inflammation. Abbreviations: DAMPs,
damage-associated molecular patterns; PAMPs, pathogen-associated
molecular patterns; ROS, reactive oxygen species; TLR4, toll-like receptor 4.
POTENTIAL THERAPEUTICS TARGETING
INFLAMMATION AND ROS
Considering ROS formation is common in asthma and COPD,
the use of free radical scavengers, such as resveratrol, NAC,
hydrogen sulfide (H2S), and molecular hydrogen (H2), may be
an effective adjuvant treatment (Kirkham and Rahman, 2006;
Ohta, 2011; Wang et al., 2012; Jiang et al., 2014). For instance,
airway hyperreactivity can be alleviated by NAC treatment
(Carlsten et al., 2014). In an animal model of allergic asthma, the
administration of NAC attenuated airway hyperresponsiveness
induced by birch pollens (Shalaby et al., 2013). In addition,
immune responses initiated by diesel exhaust exposure can be
diminished via NAC supplementation (Carlsten et al., 2014).
In an animal model for allergic asthma, resveratrol, a well-
known flavonoid, restored inositol polyphosphate 4 phosphatase
(INPP4A) activity and thus reduced allergic reactions (Aich
et al., 2012). This compound interacts with the aryl hydrocarbon
receptor (AhR), which can downregulate the expression of
pro-inflammatory genes (Revel et al., 2003). H2S is another
plausible target for the treatment of asthma because it may
serve as a molecular marker for asthma, it could be used
as a therapeutic gas, and it may act as both a hormone
and a neurotransmitter in the human body (Farrugia and
Szurszewski, 2014; Lo Faro et al., 2014). H2S can relax the smooth
muscle in intrapulmonary airways by inhibiting intracellular
Ca2+ release (Castro-Piedras and Perez-Zoghbi, 2013). On the
other hand, H2S exhibits antioxidant and anti-inflammatory
characteristics (Zhang et al., 2013). For example, exogenous H2S
can reverse ovalbumin-induced asthma (Zhang et al., 2013). The
concentration of H2S is increased in the sputum supernatants
and the serum of asthma patients, while lung function is
found to be inversely correlated with H2S levels in sputum
(Chung, 2014). Therefore, it is possible that H2S may serve as
a molecular marker in patients diagnosed with asthma (Chung,
2014).
Interestingly, H2 appears to be another effective ROS
scavenging drug (Ohno et al., 2012). In a rat model of COPD,
the beneficial effects of the injection of H2-enriched water
included reduced mucus production and epithelium damage,
partly associated with the scavenging of free radicals by H2 (Ning
et al., 2013). The positive effects of H2-enriched saline have been
reproduced in animal models of asthma (Xiao et al., 2013). Xiao
et al. demonstrated that the application of saline enrichedwithH2
can attenuate the NFκB pathway, an important part of the TLR
radical cycle (Xiao et al., 2013). Thus, the inhalation of gaseous
H2 may be a viable treatment option for patients with asthma
and/or COPD.
CONCLUSION
Current research has shown the significance of TLRs in the
pathogenesis of respiratory diseases, such as asthma and COPD.
The role of TLRs in the immune response has been well-
documented, and polymorphisms of the TLR genes can result in
drastic changes in the severity and susceptibility of respiratory
inflammatory diseases. Several treatments targeting the TLR
pathway have been topics of ongoing research in an attempt to
minimize the severity of both diseases. Studies relating to asthma
mostly show a higher degree of activation of the TLR radical
cycle. In contrast, this cycle seems to collapse in COPD subjects.
Thus, antagonists of TLRs and anti-inflammatory drugs may
have beneficial effects in patients with asthma but not in those
with COPD. However, antioxidant therapies may be beneficial in
both diseases. Further research is necessary to explore the realm
of TLR-based treatments, as these molecules play a significant
role in the development and ongoing symptoms associated with
asthma and COPD.
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